Resources
Did you mean
Millennium Pharmaceuticals Inc. (208 results)
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Zacks.com Announces That Nadine Wong Highlights the Following Stock: Millenium Pharmaceuticals
- CHICAGO -- Nadine Wong is raising sales and earnings estimates for one cancer company, and explains why she expects 2005 to turn to profitability with upside from a massive pipeline. Read about Millenium Pharmaceuticals (NASDAQ:MLNM). Nadine Wong is editor of the Biotech Stock Report newsletter. Click here for the full...
- Research articles 2004-09-28
- Millennium Initiates Phase II Clinical Trial With VELCADE and Rituximab in Patients With Indolent Non-Hodgkin's Lymphoma
- In this article Millennium Pharmaceuticals, Inc. discusses the initiation of a multicenter phase II clinical trial of VELCADE Bortezomib for injection in combination with rituximab in patients with relapsed or refractory indolent follicular and marginal zone non-Hodgkin's lymphoma. The randomized study will assess efficacy, overall safety and tolerability of the...
- White papers 2004-05-13
- Millennium Announces Assignment of Medicare Code for Velcade (Bortezomib) for Injection
- In this article Millennium Pharmaceuticals, Inc. informs that the Center for Medicare and Medicaid Services CMS has qualified VELCADE for pass-through status and assigned it to a Healthcare Common Procedure Coding System HCPCS whereby hospitals may obtain reimbursement for VELCADE under the hospital outpatient prospective payment system OPPS effective October...
- White papers 2003-09-26
- Millennium Announces Preliminary Phase I and Phase II Findings of VELCADE (Bortezomib) for Injection in Studies of Non-Hodgkin's Lymphoma and Solid Tumors
- In this article Millennium Pharmaceuticals, Inc. discusses the results of several clinical trials with its novel oncology product VELCADE, in which early signs of anti-tumor activity were observed with VELCADE as both a single agent and in combination with other therapies. VELCADE Studied as a Single Agent in Non-Hodgkin's Lymphoma...
- White papers 2003-06-02
- Millennium Seeks European Regulatory Approval for Bortezomib (VELCADE) 3.5MG Powder for Solution for Injection
- In this article Millennium Pharmaceuticals, Inc. informs that it has submitted a complete Marketing Authorization Application MAA to the European Agency for the Evaluation of Medicinal Products EMEA for the approval of bortezomib VELCADE as a treatment for relapsed and refractory multiple myeloma. This application was submitted approximately one week...
- White papers 2003-02-04
- Millennium Submits New Drug Application for VELCADE (Bortezomib) for Injection
- In this article Millennium Pharmaceuticals, Inc. informs that it has submitted a New Drug Application NDA with the U.S. Food and Drug Administration FDA for approval to market VELCADE as a treatment for relapsed and refractory multiple myeloma. In June 2002, VELCADE was granted fast-track status by the FDA as...
- White papers 2003-01-22
- Millennium Initiates Pivotal Phase III Clinical Trial Comparing VELCADE (Bortezomib) for Injection With High-Dose Dexamethasone in Patients With Multiple Myeloma
- In this article Millennium Pharmaceuticals, Inc. discusses the initiation of a pivotal phase III clinical trial of VELCADE (formerly known as MLN341, LDP-341 and PS-341) in patients with multiple myeloma, the second most common hematologic cancer. The company also announced they have filed the trade name VELCADE, for trademark registration,...
- White papers 2002-06-11
- Millennium Announces VELCADE (Bortezomib) for Injection has Significantly Extended Survival in Phase III (APEX) Trial of Patients With Relapsed Multiple Myeloma
- In this article Millennium Pharmaceuticals, Inc. discuses their final survival endpoint analysis in the phase III confirmatory APEX study comparing patients receiving VELCADE to those receiving high-dose dexamethasone, VELCADE produced a statistically significant survival benefit. The study was designed to include survival as a secondary endpoint and allowed crossover for...
- White papers
- Millennium Initiates Phase II Clinical Trial With VELCADE (Bortezomib) for Injection in Patients With Relapsed or Refractory Mantle Cell Lymphoma
- In this article Millennium Pharmaceuticals, Inc. discusses the initiation of a multicenter phase II clinical trial of VELCADE in patients with relapsed or refractory mantle cell lymphoma. The single-arm, open-label, three-stage study will assess time to progression, response rate, duration of response and overall survival in patients with relapsed or...
- White papers
- Millennium Announces Promising Early Study Results With VELCADE (Bortezomib) for Injection Combined With Doxil in Patients With Advanced Multiple Myeloma
- In this article Millennium Pharmaceuticals, Inc. discusses the preliminary phase I study results, examining the use of its novel oncology product, VELCADE, in combination with DOXILR doxorubicin liposome injection for the treatment of patients with advanced stage multiple myeloma that have failed multiple prior treatments. Also presented was a combination...
- White papers
- Millennium Initiates Phase II Clinical Trial With Velcade (Bortezomib) for Injection fn Patients With Advanced Non-Small Cell Lung Cancer
- In this article Millennium Pharmaceuticals, Inc. discusses the initiation of a phase II clinical trial of VELCADE in patients with stage IIIb locally advanced or stage IV metastatic non-small cell lung cancer NSCLC. The randomized, open-label study will assess response rates of patients with previously treated NSCLC to treatment with...
- White papers
- Millennium Initiates Phase II Clinical Trial With VELCADE (Bortezomib) for Injection in Patients With Colorectal Cancer
- In this article Millennium Pharmaceuticals, Inc. discusses the recent initiation of a phase II clinical trial of VELCADE in patients with colorectal cancer. The randomized, open-label study assesses the response rates of patients with refractory metastatic colorectal cancer to treatment with VELCADE alone or VELCADE plus CamptosarR irinotecan hydrochloride injection....
- White papers
Additional Resources
- Takeda cancer drug
- Japanese drug maker Takeda Pharmaceutical Co.'s Velcade has been given FDA approval for use on patients with previously untreated multiple myeloma. Velcade, previously approved for multiple myeloma patients who had tried another treatment unsuccessfully, was developed by Millennium Pharma, a biotechnology company recently acquired by Takeda...
- Articles 2008-07-14
- Acquisitive Takeda snaps up biotech Millennium
- TAKEDA Pharmaceutical of Japan announced plans to purchase US biotech firm Millennium Pharmaceutical in a deal valued at nearly $9 billion. The deal is the largest transaction involving a Japanese company so far this year and brings the Osaka-based Takeda a new therapeutic area-cancer treatments. Millennium Pharmaceutical's leading...
- Articles 2008-05-01
- Zacks Bull and Bear of the Day Highlights: Millennium Pharmaceuticals, Arkansas Best, Apple, Inc., Johnson Controls and Telefonica
- CHICAGO -- Zacks Equity Research highlights Millennium Pharmaceuticals (Nasdaq: MLNM) as the Bull of the Day and Arkansas Best Corporation (Nasdaq: ABFS) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Apple, Inc. (Nasdaq: AAPL), Johnson Controls (NYSE: JCI) and Telefonica (NYSE: TEF). Full analysis...
- Articles 2008-04-14
- Nereus Pharmaceuticals to Present Research at the Annual Meeting of the American Society of Hematology
- SAN DIEGO -- Nereus Pharmaceuticals, Inc., a pioneer in the use of marine microbial sources for the discovery and development of cancer therapeutics, and its collaborators will present preclinical study results involving its cancer drug candidate NPI-0052 at the 49th Annual Meeting of the American Society of Hematology ASH in...
- Articles 2007-11-26
- NCCN Updates Multiple Myeloma Guidelines
- JENKINTOWN, Pa. -- The National Comprehensive Cancer Network NCCN announces important updates to the NCCN Multiple Myeloma Guidelines. The NCCN Clinical Practice Guidelines in Oncology[TM] are widely recognized and applied as the standard of care in oncology in the United States in both the community and the academic practice settings....
- Articles 2007-10-23
- Recently Approved
- AzaSite The Food and Drug Administration has approved Durham, NC-based Inspire Pharmaceuticals Inc.'s AzaSite azithromycin ophthalmic solution 1% for the treatment of bacterial conjunctivitis. Inspire, which recently licensed the drug from Alameda, CA-based InSite Vision Inc., expects to launch it in the third quarter of this year. Doxil Bridgewater, NJ-based...
- Articles 2007-07-01
- Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of QUADRAMET® at International Myeloma Workshop
- Novel combination regimen of QUADRAMET with the protease inhibitor, bortezomib, well-tolerated with patients receiving up to four doses; preparations underway for follow-up Phase 2 study PRINCETON, N.J. -- Cytogen Corporation (NASDAQ: CYTO) reported updated data from a Phase 1 dose escalation study evaluating QUADRAMET([R]) (samarium Sm-153 lexidronam injection)...
- Articles 2007-06-28
- Bortezomib receives new indication for lymphoma
- The FDA granted approval to bortezomib (Velcade[R], Millennium Pharmaceuticals, Inc.), a proteasome inhibitor, for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. Full prescribing information, including clinical trial information, safety, dosing, drug-drug interactions, and contraindications, is available at www.fda.gov/cder/foi/label/2006/021602s010lbl.pdf. [ILLUSTRATION...
- Articles 2007-05-01
- << Previous
- page 1 of 1
- Next >>
Content Types
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
- Dell: Built to fit your business needs.
-
Powerful, Dell is built to fit your business needs Customized systems, experts trained in small business, 24/7/365 support, and powerful, reliable technology. Dell, big results for small business.
- Learn More >>
